Keytruda 100mg Injection 4ml

Description

Keytruda (pembrolizumab) is a programmed death receptor-1 (PD-1)-blocking antibody used for the treatment of various types of cancer, including:

Melanoma:

• for the treatment of patients with unresectable or metastatic melanoma.
• for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma after complete resection.

Non-Small Cell Lung Cancer (NSCLC):

• in conjunction with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.
• in conjunction with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC.
• as a monotherapy for the first-line treatment of patients with NSCLC expressing PD-L1, with no EGFR or ALK genomic tumor aberrations, and is stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.
• as a monotherapy for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%), with disease progression on or after platinum-containing chemotherapy.
• for the treatment of patients with resectable (tumors ≥4 cm or node-positive) NSCLC along with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
• as a monotherapy, for adjuvant treatment after resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC.

Head and Neck Squamous Cell Cancer (HNSCC):

• in conjunction with platinum and FU for the first-line treatment of patients with metastatic or unresectable, recurrent HNSCC.
• as a monotherapy for the first-line treatment of patients with metastatic or unresectable, recurrent HNSCC whose tumors express PD-L1.
• as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.

Classical Hodgkin Lymphoma (cHL):

• for the treatment of adult patients with relapsed or refractory cHL.
• for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after two or more lines of therapy.

Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 

• for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy.

Urothelial Cancer:

• in conjunction with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
• as a monotherapy for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy, or who have disease progression during or after platinum-containing chemotherapy or within 1 year of neoadjuvant or adjuvant therapy with platinum-containing chemotherapy.
• as a monotherapy for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Microsatellite Instability-High or Mismatch Repair Deficient Cancer:

• for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, that have progressed following prior therapy and who have no satisfactory alternative options.

Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC):